Authors
Latest:
Dr Jones on Clinical Fracture Incidence in mHSPCCraig Jones, MBChB, discusses findings from an analysis of fracture incidence in patients with metastatic hormone-sensitive prostate cancer from the phase 2/3 STAMPEDE trial platform protocol.
Latest:
Dr Porter on Mirvetuximab Soravtansine Plus Pembrolizumab in FRα+ pMMR/MSS Endometrial CancerRebecca L. Porter, MD, PhD, discusses the evaluation of mirvetuximab soravtansine plus pembrolizumab in FRα-positive, pMMR/MSS endometrial cancer.
Latest:
Dana-Farber Cancer Institute and the Florez Laboratory Set to Launch Innovative Pregnancy and Lung Cancer RegistryThe Florez Lab at Dana-Farber Cancer Institute is launching the innovative International Pregnancy and Lung Cancer Registry.
Latest:
Q&A: Final Questions on Glioblastoma and NeuroimagingNathalie Albert, MD, and Matthias Preusser, MD, address audience questions and share their insights on promising and anticipated advancements in neuroimaging techniques, highlighting the potential impact of these emerging strategies on the diagnosis, monitoring, and treatment of glioblastoma.
Latest:
Quality Over Quantity: What Concierge Medicine Can Offer to Patients With Cancer and EmployersThe current health care economy has driven many employers to self-funding models to offer affordable health care coverage to employees.
Latest:
Bispecific Antibodies May Revolutionize the Management of B-Cell LymphomaThe safety profiles and the high response rates observed with bispecific antibodies in patients with B-cell lymphoma suggest that these agents possess the potential to revolutionize the management of these diseases, particularly follicular lymphoma.
Latest:
Importance of Early Diagnosis of MDS for Lower and Higher-risk PatientsHetty Carraway, MD, highlights the importance of early diagnosis across all patients with MDS.
Latest:
The Microbiome and Colon Cancer: Dietary Influence on Incidence, Morbidity, and MortalityOne of the prime risk factors for CRC is the consumption of a high-risk, Western-style diet high in processed foods, refined grains, red meat, and sugar.
Latest:
Dr. Osman on the SELECT-MDS Trial in Higher-Risk Myelodysplastic SyndromeAfaf E. Osman, MD, discusses the phase 3 SELECT-MDS trial in patients with higher-risk myelodysplastic syndrome.
Latest:
Drs Edelman and Fleisher on Personalizing and Adapting Treatment Approaches in Clinical TrialsMartin Edelman, MD, and Linda Fleisher, PhD, MPH, discuss their role within the Stand Up To Cancer® 4-team initiative, focusing on diversity in early-phase clinical trials.
Latest:
Dr. Gulati on the Prevalence of TSC1 and TSC2 Mutations in Solid TumorsGunsagar Gulati, MD, discusses the prevalence of TSC1 and TSC2 mutations in solid tumors.
Latest:
Dr. Edington on the Utilization of TVEC Therapy in MelanomaHoward D. Edington, MD, discusses the use of talimogene laherparepvec in melanoma.
Latest:
OncLive Peer Exchange on Allo-HSCT: Conclusion of DiscussionThe expert panel recaps and synthesizes key points and conclusions from each presentation and discussion over the course of the program.
Latest:
Dr. Wang on the Potential Utility of Ruxolitinib in Pediatric Patients With cGVHDYunZu Michele Wang, MD, discusses the potential utility of ruxolitinib in children and young adult patients with chronic graft-versus-host disease.
Latest:
Dr Miranda-Galvis on the Investigation of Social Determinants of Health in Hematologic MalignanciesMarisol Miranda-Galvis, DDS, MS, PhD, discusses the investigation of disparities in survival outcomes of patients with hematologic malignancies relating to social determinants.
Latest:
The Investigational Pipeline for Advanced BTCMilind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient discuss ongoing research efforts in advanced biliary tract cancer.
Latest:
Dr Olson on the Potential Benefit of Lifileucel in Relapsed/Refractory Metastatic MelanomaDaniel Olson, MD, discusses the benefit associated with lifileucel in patients with unresectable or metastatic melanoma.
Latest:
Dr. Alldredge on Managing AEs With PARP Inhibitors in Ovarian CancerJill Alldredge, MD, discusses the toxicities associated with PARP inhibition and the management of those adverse effects in patients with ovarian cancer.
Latest:
Dr. Torres-Roca on Optimizing Radiation Therapy With GARD-Based Dosing in OncologyJavier Torres-Roca, MD, discusses optimizing radiation therapy with genomic-adjusted radiation dose–based radiotherapy dosing in oncology.
Latest:
Dr Badami on Factors Informing Treatment Selection in ccRCC and Non–ccRCCAmi Umesh Badami, MD, discusses the factors that guide treatment decision-making for patients with clear cell or non–clear cell renal cell carcinoma.
Latest:
Dr Gill on the Efficacy and Genomic Features of Ropeginterferon Alfa-2B in MyelofibrosisHarry Gill, MD, FRCP, FRCPath, discusses updated efficacy data and analysis of genomic characteristics for ropeginterferon alfa-2B in primary myelofibrosis.
Latest:
Dr. Sinha on the Antitumor Effects of Onvansertib in a Preclinical Endometroid Endometrial Cancer ModelNikita Sinha, MD, discusses the potential effects of onvansertib on endometroid endometrial cancer pathogenesis in a preclinical model.
Latest:
Dr Eckfeldt on the Implications of Improved MRD Testing in AMLCraig Eckfeldt, MD, PhD, discusses how improved minimal residual disease testing methods have impacted the acute myeloid leukemia treatment paradigm.
Latest:
Horton on Addressing the Equity Gap of Genetic Testing in Cancer CareCarrie Horton, MS, CGC, discusses the importance of addressing the equity gap of genetic testing in cancer care.
Latest:
Dr Chalasani on the Potential Utility of Eftilagimod Alpha in HER2–/HER2-Low Breast CancerPavani Chalasani, MD, MPH, discusses the potential clinical significance of the AIPAC-003 trial of eftilagimod alpha in HER2–/HER2-low breast cancer.
Latest:
Dr Qin on Areas of Active and Future Investigation in NSCLCAngel Qin, MD, discusses several areas of active investigation in non–small cell lung cancer, and highlights questions necessitating future research in this disease space.
Latest:
Real-World Treatment Reveals Discrepancy Between Actual Care and Clinical Trial Recommendations in MCLA study of treatment patterns in adult patients with mantle cell lymphoma revealed a discrepancy between actual patterns of care and recommendations based on clinical trials.
Latest:
The Desire to Always Do MoreJaffer A. Ajani, MD, has an unyielding drive that has resulted in breakthroughs in a deadly, but often overlooked, disease.
.jpg?fit=crop&auto=format)
